Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth
US6723316B2 · kind B2 · utility
34Cited by
3References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 18, 2000 |
| Grant date | Apr 20, 2004 |
| Priority date | — |
| Expiry date | Dec 18, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16661
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex virus, which is cytopathic to susceptible target cells, such as neoplastic cells. Preferably, the virus does not produce a functionally active wild-type gC polypeptide coded for the UL44 gene.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.